Salarius Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 22, 2024
DCOY$1.10-2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| 2023 | 2022 | |
|---|---|---|
| Operating expenses: | ||
| Research and development | 7,173,747 | 15,836,828 |
| General and administrative | 5,721,197 | 7,138,403 |
| Loss on impairment of goodwill | — | 8,865,909 |
| Total operating expenses | 12,894,944 | 31,841,140 |
| Loss before other income (expense) | (12,894,944) | (31,841,140) |
| Change in fair value of warrant liability | — | 14,454 |
| Interest income | 352,251 | 218,730 |
| Net loss | $(12,542,693) | $(31,607,956) |
| Loss attributable to common stockholders | $(12,542,693) | $(31,607,956) |
| Loss per common share — basic and diluted | $(3.84) | $(14.88) |
| Total net loss per share | $(3.84) | $(14.88) |
| Weighted-average number of common shares outstanding — basic and diluted | 3,264,620 | 2,124,511 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.